Monopar Therapeutics to Present at Upcoming Investor Conferences
Monopar Therapeutics Inc. (Nasdaq: MNPR), a biopharmaceutical company focused on cancer therapeutics, announced upcoming presentations by CEO Chandler D. Robinson at several investor conferences in March.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Monopar Therapeutics Inc. (Nasdaq: MNPR), a biopharmaceutical company focused on cancer therapeutics, announced upcoming presentations by CEO Chandler D. Robinson at several investor conferences in March. The presentations include:
- H.C. Wainwright Global Life Sciences Conference on March 9, 2021, at 7:00 a.m. ET.
- 33rd Annual Roth Conference on March 16, 2021, at 12:00 p.m. ET.
- Maxim’s 2021 Emerging Growth Virtual Conference on March 17, 2021, with the timing to be determined.
Monopar develops therapeutics aimed at improving cancer patients' lives.
Details
News Market Reaction – MNPR
The recorded move for MNPR in the trading session of this news was +5.31%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
WILMETTE, Ill., Feb. 24, 2021 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company primarily focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients, today announced that Chandler D. Robinson, MD, Chief Executive Officer, is planning to present a Company overview at the following investor conferences in March:
H.C. Wainwright Global Life Sciences Conference
The Company’s presentation will be webcast on Tuesday, March 9, 2021 at 7:00 a.m. ET
33rd Annual Roth Conference, Healthcare
The Company’s fireside chat will be webcast on Tuesday, March 16, 2021 at 12:00 p.m. ET
Maxim’s 2021 Emerging Growth Virtual Conference
Presentation time to be determined on Wednesday, March 17, 2021
About Monopar Therapeutics Inc.
Monopar Therapeutics is a clinical-stage biopharmaceutical company primarily focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. Monopar’s pipeline consists of Validive® for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients; camsirubicin for the treatment of advanced soft tissue sarcoma; and a late-stage preclinical antibody, MNPR-101, for advanced cancers and severe COVID-19. For more information, visit: www.monopartx.com.
CONTACT:
Monopar Therapeutics Inc:
Investor Relations
Kim R. Tsuchimoto
Chief Financial Officer
kimtsu@monopartx.com
Follow Monopar on social media for updates:
Twitter: @MonoparTx LinkedIn: Monopar Therapeutics
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.